Brief: Freeline Therapeutics Holdings - Both U.S. FDA And European Commission Have Granted Orphan Drug Designation For Flt201 For Treatment Of Gaucher Disease.

Freeline Therapeutics Holdings

09/09/2021 13:14

Sept 9 (Reuters) - Freeline Therapeutics Holdings PLC
 FRLN.O :
    * FREELINE THERAPEUTICS HOLDINGS - BOTH U.S. FDA AND
EUROPEAN
COMMISSION HAVE GRANTED ORPHAN DRUG DESIGNATION FOR FLT201 FOR
TREATMENT OF GAUCHER DISEASE.

Source text for Eikon:  ID:nGNXbjy08m 
Further company coverage:  FRLN.O 

 ((Reuters.Briefs@thomsonreuters.com;))